Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection

N. Campo, R. Brizzolara, N. Sinelli, F. Puppo, A. Campelli, F. Indiveri, A. Picciotto

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background/Aims: To evaluate the HGV infection prevalence in a group of intravenous drug users with or without human immunodeficiency virus coinfection. Methodology: We studied 57 patients (48 males and 9 females) who were either previous or still ongoing intravenous drug users. Thirty-seven patients were HIV+ve, 55 patients were anti-HCV+ve and 3 patients were HBsAg chronic carriers. Patient sera were tested for HGV-RNA, anti-E2, qualitative and quantitative HCV-RNA as well as for HCV genotypes. Moreover, the ALT level was checked in the serum sample of each patient. Results: We found a high prevalence (35/57; 61.4%) of HGV infection in our patients. HGV-RNA was detected in 16 out of the 57 intravenous drug users (28%). In particular HGV-RNA was positive in 12 out of the 37 HIV+ve patients (32.4%) and in 4 out of the 20 HIV-ve patients (20%). Anti-E2 were detected in 19 out of the 57 patients (33.3%) with greater prevalence among HIV-ve subjects (12/20; 60%) compared to HIV+ve group (7/37; 18.9%). This resulting difference was statistically significant (P

Original languageEnglish
Pages (from-to)1385-1388
Number of pages4
JournalHepato-Gastroenterology
Volume47
Issue number35
Publication statusPublished - 2000

Fingerprint

GB virus C
Virus Diseases
Drug Users
HIV
RNA
Hepatitis B Surface Antigens
Infection
Serum
Coinfection
Genotype

Keywords

  • Anti-E2
  • Hepatitis C virus
  • Hepatitis G virus
  • HGV-RNA
  • HIV infection
  • Intravenous drug users

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Campo, N., Brizzolara, R., Sinelli, N., Puppo, F., Campelli, A., Indiveri, F., & Picciotto, A. (2000). Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection. Hepato-Gastroenterology, 47(35), 1385-1388.

Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection. / Campo, N.; Brizzolara, R.; Sinelli, N.; Puppo, F.; Campelli, A.; Indiveri, F.; Picciotto, A.

In: Hepato-Gastroenterology, Vol. 47, No. 35, 2000, p. 1385-1388.

Research output: Contribution to journalArticle

Campo, N, Brizzolara, R, Sinelli, N, Puppo, F, Campelli, A, Indiveri, F & Picciotto, A 2000, 'Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection', Hepato-Gastroenterology, vol. 47, no. 35, pp. 1385-1388.
Campo N, Brizzolara R, Sinelli N, Puppo F, Campelli A, Indiveri F et al. Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection. Hepato-Gastroenterology. 2000;47(35):1385-1388.
Campo, N. ; Brizzolara, R. ; Sinelli, N. ; Puppo, F. ; Campelli, A. ; Indiveri, F. ; Picciotto, A. / Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection. In: Hepato-Gastroenterology. 2000 ; Vol. 47, No. 35. pp. 1385-1388.
@article{a10177813fec49eb8c213e1aa82259c4,
title = "Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection",
abstract = "Background/Aims: To evaluate the HGV infection prevalence in a group of intravenous drug users with or without human immunodeficiency virus coinfection. Methodology: We studied 57 patients (48 males and 9 females) who were either previous or still ongoing intravenous drug users. Thirty-seven patients were HIV+ve, 55 patients were anti-HCV+ve and 3 patients were HBsAg chronic carriers. Patient sera were tested for HGV-RNA, anti-E2, qualitative and quantitative HCV-RNA as well as for HCV genotypes. Moreover, the ALT level was checked in the serum sample of each patient. Results: We found a high prevalence (35/57; 61.4{\%}) of HGV infection in our patients. HGV-RNA was detected in 16 out of the 57 intravenous drug users (28{\%}). In particular HGV-RNA was positive in 12 out of the 37 HIV+ve patients (32.4{\%}) and in 4 out of the 20 HIV-ve patients (20{\%}). Anti-E2 were detected in 19 out of the 57 patients (33.3{\%}) with greater prevalence among HIV-ve subjects (12/20; 60{\%}) compared to HIV+ve group (7/37; 18.9{\%}). This resulting difference was statistically significant (P",
keywords = "Anti-E2, Hepatitis C virus, Hepatitis G virus, HGV-RNA, HIV infection, Intravenous drug users",
author = "N. Campo and R. Brizzolara and N. Sinelli and F. Puppo and A. Campelli and F. Indiveri and A. Picciotto",
year = "2000",
language = "English",
volume = "47",
pages = "1385--1388",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "35",

}

TY - JOUR

T1 - Hepatitis G virus infection in intravenous drug users with or without human immunodeficiency virus infection

AU - Campo, N.

AU - Brizzolara, R.

AU - Sinelli, N.

AU - Puppo, F.

AU - Campelli, A.

AU - Indiveri, F.

AU - Picciotto, A.

PY - 2000

Y1 - 2000

N2 - Background/Aims: To evaluate the HGV infection prevalence in a group of intravenous drug users with or without human immunodeficiency virus coinfection. Methodology: We studied 57 patients (48 males and 9 females) who were either previous or still ongoing intravenous drug users. Thirty-seven patients were HIV+ve, 55 patients were anti-HCV+ve and 3 patients were HBsAg chronic carriers. Patient sera were tested for HGV-RNA, anti-E2, qualitative and quantitative HCV-RNA as well as for HCV genotypes. Moreover, the ALT level was checked in the serum sample of each patient. Results: We found a high prevalence (35/57; 61.4%) of HGV infection in our patients. HGV-RNA was detected in 16 out of the 57 intravenous drug users (28%). In particular HGV-RNA was positive in 12 out of the 37 HIV+ve patients (32.4%) and in 4 out of the 20 HIV-ve patients (20%). Anti-E2 were detected in 19 out of the 57 patients (33.3%) with greater prevalence among HIV-ve subjects (12/20; 60%) compared to HIV+ve group (7/37; 18.9%). This resulting difference was statistically significant (P

AB - Background/Aims: To evaluate the HGV infection prevalence in a group of intravenous drug users with or without human immunodeficiency virus coinfection. Methodology: We studied 57 patients (48 males and 9 females) who were either previous or still ongoing intravenous drug users. Thirty-seven patients were HIV+ve, 55 patients were anti-HCV+ve and 3 patients were HBsAg chronic carriers. Patient sera were tested for HGV-RNA, anti-E2, qualitative and quantitative HCV-RNA as well as for HCV genotypes. Moreover, the ALT level was checked in the serum sample of each patient. Results: We found a high prevalence (35/57; 61.4%) of HGV infection in our patients. HGV-RNA was detected in 16 out of the 57 intravenous drug users (28%). In particular HGV-RNA was positive in 12 out of the 37 HIV+ve patients (32.4%) and in 4 out of the 20 HIV-ve patients (20%). Anti-E2 were detected in 19 out of the 57 patients (33.3%) with greater prevalence among HIV-ve subjects (12/20; 60%) compared to HIV+ve group (7/37; 18.9%). This resulting difference was statistically significant (P

KW - Anti-E2

KW - Hepatitis C virus

KW - Hepatitis G virus

KW - HGV-RNA

KW - HIV infection

KW - Intravenous drug users

UR - http://www.scopus.com/inward/record.url?scp=0033769594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033769594&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 1385

EP - 1388

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 35

ER -